Biopharma Quarterly Dealmaking Statistics, Q3 2016
A look at financing, M&A and alliance activity July–September 2016
Executive Summary
In Q3, biopharma financing totaled $7.4 billion, a large proportion of which was by rare disease developers; among the highlights in the $23 billion in M&As was Allergan's buying spree, including two NASH companies. Just over $20 billion went into biopharma alliance dealmaking, and neurology assets attracted many of the dollars.
You may also be interested in...
Regeneron’s Fasinumab Brings Second Clinical Hold For Anti-NGF Class
One case of adjudicated arthropathy seen in halted Phase IIb study of anti-NGF candidate. Regeneron still hopes to advance fasinumab, partnered with Teva, into Phase III in osteoarthritis and chronic low back pain – but the second clinical hold for the class puts its future into even greater question.
Medigene's bluebird Deal Validates TCR Technology And Immune-Oncology Strategy
Medigene's collaboration with bluebird bio is a validation of its technology platform and its new immune-oncology focused strategy.
Allergan’s Tab For Tobira’s NASH Cocktail With Akarna Chaser Tops $1.7bn
Allergan will pay a huge premium – up to $1.7bn in a milestone-heavy deal – for Tobira and $50m up front for the preclinical startup Akarna to expand its gastrointestinal franchise into the potentially lucrative NASH market.